These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 21428824)

  • 1. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
    Cox KJ; Shomin CD; Ghosh I
    Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.
    Lamba V; Ghosh I
    Curr Pharm Des; 2012; 18(20):2936-45. PubMed ID: 22571662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting polypharmacology by binding site similarity: from kinases to the protein universe.
    Milletti F; Vulpetti A
    J Chem Inf Model; 2010 Aug; 50(8):1418-31. PubMed ID: 20666497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
    Sheinerman FB; Giraud E; Laoui A
    J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
    Dar AC; Shokat KM
    Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence and structural analysis of kinase ATP pocket residues.
    Vulpetti A; Bosotti R
    Farmaco; 2004 Oct; 59(10):759-65. PubMed ID: 15474052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors.
    Jahnke W; Blommers MJ; Fernández C; Zwingelstein C; Amstutz R
    Chembiochem; 2005 Sep; 6(9):1607-10. PubMed ID: 16028302
    [No Abstract]   [Full Text] [Related]  

  • 11. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
    Prudent R; Cochet C
    Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent inhibitors of protein kinases.
    Gower CM; Chang ME; Maly DJ
    Crit Rev Biochem Mol Biol; 2014; 49(2):102-15. PubMed ID: 24564382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in the design of selective ATP-competitive kinase inhibitors].
    Deng XQ; Xiang ML; Jia R; Yang SY
    Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.
    Huang D; Zhou T; Lafleur K; Nevado C; Caflisch A
    Bioinformatics; 2010 Jan; 26(2):198-204. PubMed ID: 19942586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
    Park H; Chi O; Kim J; Hong S
    J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
    Chuaqui C; Deng Z; Singh J
    J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doing more than just the structure-structural genomics in kinase drug discovery.
    Marsden BD; Knapp S
    Curr Opin Chem Biol; 2008 Feb; 12(1):40-5. PubMed ID: 18267130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.